- Trial phase
- Phase 3
- Time to market
- If Phase 3 trials succeed, a potential FDA submission could occur in 2028, with approval possible in 2029 at the earliest, assuming topline data reads out in 2027 and a standard ~12-month review cycle.
- Why 6/10
- The next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Since the readout is more than ~6 months out and Neurocrine is a multi-product company with INGREZZA generating over $1.1B/quarter in revenue, direclidine is a major pipeline asset but not a single-asset binary, justifying a score of 6.
The next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.
Price Chart
Executive Summary
Direclidine (NBI-1117568, HTL-0016878) is an investigational oral, selective M4 muscarinic receptor agonist being developed by Neurocrine Biosciences (NBIX) for schizophrenia, with a secondary Phase 2 program in bipolar I disorder. It is the first selective M4 orthosteric agonist to reach Phase 3 for schizophrenia. Positive Phase 2 data (August 2024) showed a statistically significant 7.5-point PANSS improvement at the 20 mg dose. A multi-study Phase 3 registrational program began in August 2025, with topline data expected in 2027. The drug competes in the emerging muscarinic agonist class against Bristol Myers Squibb's already-approved Cobenfy (KarXT). Neurocrine is a well-capitalized company with its marketed product INGREZZA generating over $1.1B in quarterly revenue, meaning direclidine is a major pipeline catalyst but not a make-or-break binary for the company.
How It Works
Direclidine is a selective activator (agonist) of the M4 muscarinic receptor, a type of docking station on brain cells that responds to the neurotransmitter acetylcholine. By activating M4 receptors, the drug indirectly calms overactive dopamine signaling in brain regions linked to psychosis, without directly blocking dopamine receptors the way most older antipsychotics do. This mechanism is intended to treat schizophrenia symptoms with a potentially different side-effect profile than standard antipsychotics.
Trial Status
Direclidine is in a multi-study Phase 3 registrational program for schizophrenia initiated in August 2025. Multiple trials are recruiting: an inpatient acute exacerbation study (NCT07105098, primary completion Nov 2027), a relapse prevention study (NCT07227818, recently expanded to 25 sites), and a long-term safety study (NCT07114874). A Phase 2 study for bipolar I disorder (NCT07288320) is also recruiting. Topline Phase 3 data for schizophrenia is expected in 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (specific quarter not yet guided)
- Phase 2 topline data for direclidine in bipolar I disorder (mania) - timeline not yet specified
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report